Update on Immunotherapeutics in the Management of Metastatic Melanoma

Skin Therapy Lett. 2019 Jan;24(1):8-11.

Abstract

Today, a number of treatment options are now available for metastatic melanoma. Within the last decade, the development of novel immunotherapies for cancer has significantly altered the course of the disease in patients with melanoma. With more patients receiving these potentially life-saving treatments, not only have we learned more about the interplay between the immune system and melanoma, but more importantly, which treatment options are most appropriate given the clinical picture.

Keywords: immunotherapy; melanoma; update; checkpoint inhibitors; BRAF.

MeSH terms

  • CTLA-4 Antigen / antagonists & inhibitors
  • Humans
  • Immunotherapy / methods*
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Neoplasm Metastasis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors

Substances

  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins B-raf
  • Mitogen-Activated Protein Kinase Kinases